Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?
Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.
Amgen and Johnson & Johnson are two prominent players in the healthcare industry, each offering investors unique opportunities and risks. Amgen, a biotech pioneer, focuses on developing biological medicines for complex diseases such as inflammation, oncology, and rare conditions. The company reported a revenue of approximately $36.7 billion in FY 2025, marking a 10% growth compared to the previous year.
Net income reached around $7.7 billion, yielding a net margin of roughly 21%. However, Amgen faces potential risks due to drug price scrutiny, manufacturing concentration in Puerto Rico and California, and a tax dispute with the IRS. Its debt-to-equity ratio is notably high at nearly 6.3x, and its current ratio stands at approximately 1.1x.
Despite these challenges, Amgen boasts six drug franchises generating over $1 billion in annual revenue each, and recent negotiations with the U.S. government to lower drug prices provide a positive outlook.
On the other hand, Johnson & Johnson operates through two segments: Innovative Medicine and MedTech. Its Innovative Medicine segment boasts 28 products and platforms generating more than $1 billion in annual revenue, with recent FDA approvals and upcoming drug product launches. MedTech offers a wide range of healthcare products, from wound care to spinal implants.
Johnson & Johnson reported a revenue of roughly $94.2 billion in FY 2025, a 6% increase from the previous fiscal year, and net income of approximately $26.8 billion, resulting in a net margin of 28.5%. The company's debt-to-equity ratio is significantly lower at approximately 0.6x, and its current ratio is close to 1.0x. However, Johnson & Johnson faces challenges such as pricing and reimbursement headwinds from global healthcare reforms, legal proceedings related to product liability claims, and intense competition from pharmaceutical leaders like Pfizer and AbbVie.
Despite these obstacles, Johnson & Johnson's strong asset base and robust pipeline of approved drugs make it an appealing option for investors seeking stability and long-term value.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
